An observational study in Sarcoma, Survivorship and Quality of Life (QOL), sponsored by Technische Universität Dresden. Recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Technische Universität Dresden · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.
Among the 103 studies in Sarcoma with a site in Germany, this one is the 4th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2025, is one of 19 observational ones, reaches primary completion later than 15 of the 29 other live ones, and was the 100th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:
Universität Duisburg-Essen · Sites in Germany
Ages 15+
Technical University of Munich · Sites in Germany
Novartis Pharmaceuticals · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
Adcendo ApS · Sites in Germany, United States, Belgium and 2 more countries
Ages 18+
Heidelberg University · Sites in Germany, Switzerland
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 44 · Phase 3 19
First in 1995; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 120 across 220 observational studies indexed under Sarcoma.
Median enrollment 103 across the 83 interventional studies, 130 across the 19 observational. Of the 69 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 103 have an industry lead sponsor. The 10 most frequent:
Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.
Technische Universität Dresden has 2 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcoma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT05492682Valo Therapeutics OySTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | 2027-04-30 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07148193Technische Universität DresdenQuality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+) | 2027-09 |
| NCT06743958Technical University of MunichPrehabilitation in Childhood Soft Tissue or Bone Sarcomas | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Sarcoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Sarcomas are rare cancers that can arise almost anywhere in the body and account for only about one percent of all cancer diagnoses. Both the disease and its treatments often result in late effects, yet knowledge about these long-term consequences remains limited. The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. Particular focus is placed on subgroups with potential long-term risks, including survivors of bone sarcomas, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, gastrointestinal stromal tumors (GIST) with or without long-term TKI therapy, and young adult survivors.
The mixed-methods research design includes a multicenter observational study with a one-time questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Recruitment is built on draws on existing network structures, including the PROSa cohort, the National Center for Tumor Diseases (NCT/UCC) Dresden, the SarcBOP registry at the National Center for Tumor Diseases (NCT) Heidelberg, West German Cancer Center Essen (WTZ), University Hospital Mannheim (UMM), the German Sarcoma Foundation, and cooperating sarcoma centers. Medical data are extracted from patient records.
Statistical analyses will include descriptive statistics and regression models to identify impaired quality of life domains and associated factors.
Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.
Other: No intervention (observational study)
No intervention (observational study)
Quality of Life (EORTC QLQ-SURV100)
The EORTC QLQ-SURV100 is a 100-item questionnaire assessing general quality of life among cancer survivors. It includes multiple functional scales covering physical, role, emotional, cognitive, and social functioning, as well as symptom scales (fatigue, pain) and several single-item measures. Most items are rated on a 1-4 scale, while two global items on overall quality of life and general health are rated on a 1-7 scale. Higher scores on the functional and global health status scales indicate better quality of life, whereas higher scores on symptom scales reflect worse quality of life. With the exception of five acute symptoms, the SURV100 includes all items from the EORTC QLQ-C30. To enable comparative analyses, the investigators supplemented the SURV100 with these five missing items: appetite loss, nausea, vomiting, constipation, and diarrhea.
Time frame: single-time point (enrollment)
Satisfaction with Medical Care (adapted from EORTC OUT-PATSAT7 & self-developed items)
Satisfaction with medical care and communication will be assessed using three items adapted from the EORTC OUT-PATSAT7 and three self-developed items, all rated on a 1-5 scale. Higher scores indicate greater satisfaction with the medical care received.
Time frame: single time point (enrollment)
Use of Care Offers (self-developed, adapted from CaSUN)
Service utilization will be assessed with self-developed items based on the Cancer Survivors' Unmet Needs measure (CaSUN). Participants indicate their use of 24 different non-rehabilitation care services and 11 rehabilitation care services. Response options include two types of "No" (offer not available or offer available but not used) and, if "Yes," a rating from 1-3 indicating how helpful the offer was, with higher scores reflecting greater helpfulness.
Time frame: single time point (enrollment)
Unmet Needs (self-developed, adapted from CaSUN)
Unmet needs will be assessed with self-developed items based on the CaSUN, asking participants about the lack of adequate support or services in 20 areas. Response options include two types of "No" (no need or need has already been met) and, if "Yes," a rating from 1-3 indicating the current intensity of the unmet need, with higher scores reflecting greater unmet need.
Time frame: single time point (enrollment)
Fatigue (EORTC QLQ-FA12)
Fatigue will be assessed using the 12-item EORTC QLQ-FA12 scale, which measures physical, emotional, and cognitive aspects of cancer-related fatigue on a 1-4 scale. Higher scores indicate greater fatigue.
Time frame: single-time point (enrollment)
Psychological Distress (PHQ-4)
Psychological distress will be measured using the four-item PHQ-4, including the diagnostic core criteria for depression (PHQ-2) and generalized anxiety disorder (GAD-2), ranging from 1-4. Higher scores indicate greater psychological distress.
Time frame: single-time point (enrollment)
Loneliness (UCLA LS-3)
Loneliness will be assessed using the three-item UCLA Loneliness Scale, measuring subjective feelings of loneliness and social isolation, ranging from 1-3. Higher scores indicate greater loneliness.
Time frame: single-time point (enrollment)
Physical Complaints (EORTC WISP)
Physical complaints will be measured using the EORTC WISP module, allowing participants to report up to three symptoms and rate the degree of burden from 1-4. Higher scores indicate greater impairment due to the respective symptom.
Time frame: single-time point (enrollment)
Communication with Healthcare Professionals (adapted from EORTC COMU26 & self-developed items)
Communication experiences will be assessed using nine items adapted from the EORTC COMU26 and nine self-developed items, focusing on perceived quality and clarity of communication with healthcare providers. Rated on a 1-4 scale, higher scores indicate greater satisfaction with communication.
Time frame: single-time point (enrollment)
Information Sources (self-developed, answer options adapted from CaSUN)
Information sources will be assessed using nine self-developed items, asking participants where they obtain cancer-related information. Response options include two types of "No" (not known or known but not used) and, if "Yes," a rating from 1-3 indicating how helpful the source was, with higher scores reflecting greater helpfulness.
Time frame: single-time point (enrollment)
Sociodemographic Items
Sociodemographic characteristics, including age, sex, and migration background will be collected.
Time frame: single-time point (enrollment)
Socioeconomic Items
Socioeconomic status will be assessed through items measuring i.a. education, employment status, and income.
Time frame: single-time point (enrollment)
Physical Activity (adapted Godin-Shephard Leisure-Time Physical Activity Questionnaire)
Physical activity will be measured using an adapted version of the Godin-Shephard Leisure-Time Physical Activity Questionnaire. This 4-item questionnaire evaluates the frequency and duration of mild, moderate and vigorous aerobic activities, as well as moderate-to-vigorous strength training, performed during the week. Scores reflect whether participants meet exercise guidelines: * Aerobic guidelines: ≥75 min of vigorous or ≥150 min moderate activity (meeting guidelines) vs. 0-149 minutes of moderatre and vigorous activity per week (not meeting guidelines) * Resistance guidelines: ≥2 resistance sessions/week (meeting guidelines) vs. \<2 sessions (not meeting guidelines) Higher scores indicate better adherence to physical activity recommendations.
Time frame: single-time point (enrollment)
Comorbidities
Information on comorbid conditions (e.g., cardiovascular disease, diabetes, depression) will be collected, capturing co-existing health conditions. The total number of comorbidities will be summed and used as a control variable in the analyses.
Time frame: single-time point (enrollment)
Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technische Universität Dresden →